{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T13:36:49Z","timestamp":1771076209188,"version":"3.50.1"},"reference-count":40,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2021,5,4]]},"DOI":"10.1080\/17474086.2021.1924052","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T17:16:51Z","timestamp":1620235011000},"page":"419-427","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma"],"prefix":"10.1080","volume":"14","author":[{"given":"Anna","family":"Piggin","sequence":"first","affiliation":[{"name":"Molecular Oncology and Cancer Immunology, Epworth Healthcare, Melbourne, Australia"},{"name":"Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Cancer Immunology, Epworth Healthcare, Melbourne, Australia"},{"name":"Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,5,16]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247015"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02096"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138"},{"key":"cit0004","first-page":"248","volume-title":"Hematology 2014, the american society of hematology education program book","volume":"2020","author":"Van De Donk NW","year":"2020"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.1663"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1597"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-740944"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483511"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12561"},{"key":"cit0011","volume-title":"New Jersey, USA","author":"Sanofi-Aventis. Sarclisa\u00a9 Full Prescribing Information. Reference ID","year":"2020"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2019.05.007"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13707"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-848986"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0695"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.240"},{"issue":"12","key":"cit0017","first-page":"3298","volume":"34","author":"Mikhael J","year":"2020","journal-title":"InLeukemia"},{"issue":"2","key":"cit0018","first-page":"123","volume":"134","author":"Mikhael J","year":"2019","journal-title":"Blood J Am Soc Hematol"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0868-z"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23693"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0813-1"},{"key":"cit0024","unstructured":"Dimopoulos M, editor APOLLO: Phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone (D-pd) versus pomalidomide and dexamethasone (pd) alone in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Abstract."},{"key":"cit0025","unstructured":"ClinicalTrials.gov. Comparison of pomalidomide and dexamethasone with or without daratumumab in subjects with relapsed or refractory multiple myeloma previously treated with lenalidomide and a proteasome inhibitor daratumumab\/pomalidomide\/dexamethasone vs pomalidomide\/dexamethasone (EMN14). NCT03180736. [cited 2021 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03180736."},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0711-6"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00948-5"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"cit0032","unstructured":"ClinicalTrials.gov. Multi-center, open-label, phase 1b study in patients with relapsed\/refractory multiple myeloma (RRMM). [cited 2021 Jan 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04045795"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000667"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243790"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30070-3"},{"key":"cit0036","unstructured":"ClinicalTrials.gov. Multinational clinical study comparing isatuximab, carfilzomib and dexamethasone to carfilzomib and dexamethasone in relapse and\/or refractory multiple myeloma patients (IKEMA)."},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137681"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2020.10.439"},{"key":"cit0039","unstructured":"ClinicalTrials.gov. KRDI in transplant-eligible MM."},{"key":"cit0040","volume-title":"BLOOD","author":"Becnel MR","year":"2020"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2021.1924052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T20:08:59Z","timestamp":1626811739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2021.1924052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,4]]}},"alternative-id":["10.1080\/17474086.2021.1924052"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2021.1924052","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}